Reardon Andrew sold $324K of LGND
Reardon Andrew (CLO & Secretary) sold 1,432 shares of LIGAND PHARMACEUTICALS INC (LGND) at $225.97 ($0.32M total) on 2026-06-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosure provides a datapoint on insider activity but does not introduce new company fundamentals (no earnings, trial, approval, or deal).
Market read
Traders may treat this as a low-signal sentiment item rather than a catalyst; watch for unusual follow-on insider activity or fundamental news.
What to watch
The net signal depends on whether this is part of a larger scheduled program and whether other insiders are buying/selling around the same period.
Background
This is an SEC Form 4 insider transaction disclosure for Ligand Pharmaceuticals, Inc. (LGND).
Ticker impact
SEC Form 4 shows officer Andrew Reardon sold 1,432 LGND shares in an open-market transaction under a 10b5-1 plan.
Likely limited/short-lived impact; any reaction is more sentiment-driven than fundamental.
The filing is an ownership-change disclosure with no accompanying company-specific operational or financial catalyst; 10b5-1 reduces interpretive weight.
Market effects
Minimal—single-company insider transaction without new drug/clinical/regulatory information.
None expected beyond local sentiment for LGND.
None.
Counterpoint
Even with 10b5-1, repeated insider selling can coincide with management’s risk/valuation view; monitor for follow-on sales outside planned windows.
Key entities
- public_companyLGND
Ligand Pharmaceuticals, Inc.; officer Andrew Reardon reported an open-market sale under a 10b5-1 plan.
- insiderAndrew Reardon
CLO & Secretary; sold 1,432 shares on 2026-06-01.
